BACKGROUND: Currently, limited mouse models that mimic the clinical course of castrate resistant prostate development currently exist. Such mouse models are urgently required to conduct pre-clinical studies to assist in the understanding of disease progression and the development of rational therapeutic strategies to treat castrate resistant prostate cancer. METHODS: Wild type intact FVB male mice were injected by subcutaneous injection with Myc-CaP cells to establish androgen sensitive Myc-CaP tumors. Tumor bearing mice were castrated and resulting tumors serially passaged in pre-castrated FVB male mice to produce a bone fide Myc-CaP castrate resistant tumor. RESULTS: Immunohistochemical analysis revealed that initial androgen sensitive Myc-CaP tumors had strong nuclear transcriptional active androgen receptor expression, as indicated by marked c-MYC staining and were highly proliferative. Castration of tumor bearing animals resulted in cytoplasmic relocation of androgen receptor concurrent with loss of transcriptional activity and tumor proliferation. Serial passaging of castrate refractory Myc-CaP in pre-castrated male FVB mice resulted in the development of a bona fide castrate resistant Myc-CaP tumor which pheno-copied the original androgen sensitive parental Myc-CaP tumor. CONCLUSIONS: Developing a murine castrate transplant resistant tumor model that mimics the clinical course of human castrate resistant prostate cancer will create better opportunities to understand the development of castrate resistant prostate cancer and also allow for more rapid pre-clinical studies to stratify rational novel therapies for this lethal form of prostate cancer.
BACKGROUND: Currently, limited mouse models that mimic the clinical course of castrate resistant prostate development currently exist. Such mouse models are urgently required to conduct pre-clinical studies to assist in the understanding of disease progression and the development of rational therapeutic strategies to treat castrate resistant prostate cancer. METHODS: Wild type intact FVB male mice were injected by subcutaneous injection with Myc-CaP cells to establish androgen sensitive Myc-CaP tumors. Tumor bearing mice were castrated and resulting tumors serially passaged in pre-castrated FVB male mice to produce a bone fide Myc-CaP castrate resistant tumor. RESULTS: Immunohistochemical analysis revealed that initial androgen sensitive Myc-CaP tumors had strong nuclear transcriptional active androgen receptor expression, as indicated by marked c-MYC staining and were highly proliferative. Castration of tumor bearing animals resulted in cytoplasmic relocation of androgen receptor concurrent with loss of transcriptional activity and tumor proliferation. Serial passaging of castrate refractory Myc-CaP in pre-castrated male FVB mice resulted in the development of a bona fide castrate resistant Myc-CaP tumor which pheno-copied the original androgen sensitive parental Myc-CaP tumor. CONCLUSIONS: Developing a murine castrate transplant resistant tumor model that mimics the clinical course of human castrate resistant prostate cancer will create better opportunities to understand the development of castrate resistant prostate cancer and also allow for more rapid pre-clinical studies to stratify rational novel therapies for this lethal form of prostate cancer.
Authors: Philip A Watson; Katharine Ellwood-Yen; Jennifer C King; John Wongvipat; Michelle M Lebeau; Charles L Sawyers Journal: Cancer Res Date: 2005-12-15 Impact factor: 12.701
Authors: Chun-Peng Liao; Mengmeng Liang; Michael B Cohen; Andrea Flesken-Nikitin; Joseph H Jeong; Alexander Yu Nikitin; Pradip Roy-Burman Journal: Horm Cancer Date: 2010-02 Impact factor: 3.869
Authors: Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers Journal: Science Date: 2009-04-09 Impact factor: 47.728
Authors: Leigh Ellis; Michael Bots; Ralph K Lindemann; Jessica E Bolden; Andrea Newbold; Leonie A Cluse; Clare L Scott; Andreas Strasser; Peter Atadja; Scott W Lowe; Ricky W Johnstone Journal: Blood Date: 2009-04-21 Impact factor: 22.113
Authors: Kenneth J Pienta; Cory Abate-Shen; David B Agus; Ricardo M Attar; Leland W K Chung; Norman M Greenberg; William C Hahn; John T Isaacs; Nora M Navone; Donna M Peehl; Jonathon W Simons; David B Solit; Howard R Soule; Terry A VanDyke; Michael J Weber; Lily Wu; Robert L Vessella Journal: Prostate Date: 2008-05-01 Impact factor: 4.104
Authors: Jing Jiao; Shunyou Wang; Rong Qiao; Igor Vivanco; Philip A Watson; Charles L Sawyers; Hong Wu Journal: Cancer Res Date: 2007-07-01 Impact factor: 12.701
Authors: Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers Journal: Nat Med Date: 2003-12-21 Impact factor: 53.440
Authors: Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu Journal: Cancer Cell Date: 2003-09 Impact factor: 31.743
Authors: Katharine Ellwood-Yen; Thomas G Graeber; John Wongvipat; M Luisa Iruela-Arispe; JianFeng Zhang; Robert Matusik; George V Thomas; Charles L Sawyers Journal: Cancer Cell Date: 2003-09 Impact factor: 31.743
Authors: Paula J Hurley; Robert M Hughes; Brian W Simons; Jessie Huang; Rebecca M Miller; Brian Shinder; Michael C Haffner; David Esopi; Yasunori Kimura; Javaneh Jabbari; Ashley E Ross; Nicholas Erho; Ismael A Vergara; Sheila F Faraj; Elai Davicioni; George J Netto; Srinivasan Yegnasubramanian; Steven S An; Edward M Schaeffer Journal: Cancer Res Date: 2015-08-20 Impact factor: 12.701
Authors: Li Shen; Anette Sundstedt; Michael Ciesielski; Kiersten Marie Miles; Mona Celander; Remi Adelaiye; Ashley Orillion; Eric Ciamporcero; Swathi Ramakrishnan; Leigh Ellis; Robert Fenstermaker; Scott I Abrams; Helena Eriksson; Tomas Leanderson; Anders Olsson; Roberto Pili Journal: Cancer Immunol Res Date: 2014-11-04 Impact factor: 11.151
Authors: Brian M Olson; Melissa Gamat; Joseph Seliski; Thomas Sawicki; Justin Jeffery; Leigh Ellis; Charles G Drake; Jamey Weichert; Douglas G McNeel Journal: Cancer Immunol Res Date: 2017-10-19 Impact factor: 11.151
Authors: Leigh Ellis; Kristin Lehet; Swathi Ramakrishnan; Remi Adelaiye; Kiersten M Miles; Dan Wang; Song Liu; Peter Atadja; Michael A Carducci; Roberto Pili Journal: PLoS One Date: 2011-11-07 Impact factor: 3.240
Authors: Li Shen; Michael Ciesielski; Swathi Ramakrishnan; Kiersten M Miles; Leigh Ellis; Paula Sotomayor; Protul Shrikant; Robert Fenstermaker; Roberto Pili Journal: PLoS One Date: 2012-01-27 Impact factor: 3.240